On this episode of LFI Levered Lines, host Luke Millar is joined by Peter Urquhart, melanoma survivor and Global Senior Manager at LSEG, and Stephanie Kauffman, President and Chief Operating Officer of Melanoma Research Alliance, for an in-depth discussion of groundbreaking cancer research and the upcoming LFFM London event. The conversation examines Peter's personal journey through stage 3 melanoma diagnosis at age 37, his 12-month immunotherapy treatment with minimal side effects, and his nine-month clear status, alongside the remarkable expansion from two to seventeen approved melanoma treatment options over the past 15 years and the 50% patient response rate representing quantum leaps in oncology outcomes. Stephanie discusses the alarming trend of melanoma cases in younger populations, the revolutionary development of immunotherapy now benefiting 30 other cancers, and the critical importance of early detection through AI-powered technologies being developed at Oxford University and Royal Marsden. The discussion highlights the inaugural LFFM London success—raising £1.4 million with 550 attendees—alongside research priorities addressing genetic mutations, brain metastasis, and reducing treatment side effects.